Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy

Keyphrases

• American Society 14%
• American Society of Clinical Oncology 14%
• Anecdotal Evidence 14%
• Chemoradiation 14%
• Cochrane Collaboration 14%
• Collaborative Groups 14%
• Combined Regimen 14%
• Confidence Interval 85%
• Dermatitis 14%
• Dermatologic Toxicity 100%
• Embase 14%
• Epidermal Growth Factor Receptor Inhibitors 100%
• Fixed Effects Model 14%
• Incidence Rate 14%
• Inhibitor Therapy 100%
• Locoregional Control 14%
• Management Strategy 14%
• MEDLINE 14%
• Mucositis 42%
• Oncology 14%
• Overall Effect 14%
• Phase 1 Trial 14%
• Phase II Trial 28%
• Quality of Life 14%
• Radiation Dermatitis 71%
• Radiotherapy 42%
• Random Effects 14%
• Rash 71%
• Reduced Mortality 14%
• Relative Risk 14%
• Reporting Strategies 14%
• Risk Ratio 14%
• Safety Concerns 14%
• Solid Tumors 14%
• Toxicity Data 14%

Medicine and Dentistry

• Chemoradiotherapy 14%
• Clinical Oncology 14%
• Dermatitis 14%
• Dermatological Agent 100%
• Epidermal Growth Factor Receptor Kinase Inhibitor 100%
• Exanthem 71%
• Mucositis 71%
• Oncology 14%
• Quality of Life 14%
• Radiation Dermatitis 71%
• Radiation Therapy 57%
• Solid Malignant Neoplasm 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemoradiation Therapy 14%
• Dermatitis 14%
• Dermatological Agent 100%
• Epidermal Growth Factor Receptor Kinase Inhibitor 100%
• Mucosa Inflammation 71%
• Rash 71%
• Solid Malignant Neoplasm 14%